A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs (KYANITE-1)

October 22, 2025 updated by: Krystal Biotech, Inc.

KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies.

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707.

Monotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for three weeks, then every three weeks. The dose escalation portion of the study is now complete, and the selected dose is being evaluated in the expansion phase.

Combination regimens with a selected (fixed) dose of KB707 are being evaluated in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 are receiving inhaled KB707 once every 2 weeks (q2w), delivered in combination with Keytruda once every 6 weeks. Subjects in Cohort 7 are receiving inhaled KB707 in combination with docetaxel once every 3 weeks.

All subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

250

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Alabama
      • Dothan, Alabama, United States, 36303
        • Recruiting
        • XCancer Research Network/Dothan Hematology & Oncology
        • Contact:
        • Contact:
    • Arizona
      • Scottsdale, Arizona, United States, 85258
        • Recruiting
        • HonorHealth Research Institute
        • Contact:
        • Principal Investigator:
          • Justin Moser, MD
        • Contact:
          • Oncology Clinical Trials Nurse Navigator
          • Phone Number: 833-354-6667
    • California
      • Beverly Hills, California, United States, 90212
      • Redlands, California, United States, 92373
    • Florida
      • Weston, Florida, United States, 33326
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Terminated
        • IU Simon Comprehensive Cancer Center
    • Louisiana
      • New Orleans, Louisiana, United States, 70121
        • Recruiting
        • Ochsner/MD Anderson Cancer Center
        • Contact:
        • Contact:
          • Amanda Woolery, RN, BSN
          • Phone Number: 504-842-0275
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Recruiting
        • Henry Ford Health
        • Contact:
        • Contact:
    • Ohio
      • Canton, Ohio, United States, 44718
      • Cleveland, Ohio, United States, 44195
        • Recruiting
        • Cleveland Clinic
        • Contact:
          • Cancer Answer Line
          • Phone Number: 216-444-7923
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15232
        • Terminated
        • UPMC Hillman Cancer Center
    • Tennessee
      • Nasville, Tennessee, United States, 37203
        • Recruiting
        • Sarah Cannon Research Institute
        • Contact:
    • Texas
      • El Paso, Texas, United States, 79915
        • Terminated
        • Renovatio Clinical
      • The Woodlands, Texas, United States, 77380
        • Terminated
        • Renovatio Clinical

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

  • Age 18 years or older at the time of informed consent
  • Life expectancy >12 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Have at least one measurable lung lesion per RECIST v1.1 at Screening
  • Cohorts 1 through 4 only: Histologically confirmed diagnosis of advanced solid tumor malignancy affecting the lungs and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or has no standard of care therapy.

  • Cohorts 5, 6, and 7 only: (1) Histologically or cytologically confirmed diagnosis of stage 3 or 4 NSCLC, as per American Joint Committee on Cancer (AJCC) staging system (8th edition) and (2) Subject must meet the following criteria of prior lines of therapy:

    1. Subject has previously received no more than one line of prior immune checkpoint inhibitor (ICI) with or without platinum-based chemotherapy, or no more than two prior lines of therapy when given the ICI and platinum-based chemotherapy sequentially as two separate lines.
    2. Subjects with an actionable mutation (e.g., EGFR, KRAS, ALK, or ROS1 genomic alteration), are permitted to have received one additional line of approved targeted therapy.

Key Exclusion Criteria:

  • Not fully recovered from prior surgery or radiotherapy, including all radiation-related toxicities
  • The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707
  • Have known history of positive human immunodeficiency virus (HIV 1/2)

  • Cohorts 5, 6, and 7 only:

    1. Subject has a known additional malignancy that is progressing or requires active treatment
    2. Subject has active brain metastases or leptomeningeal metastases
    3. Prior anti-PD-1/PD-L1 therapy was intolerable and required discontinuation of treatment
    4. Subject has active, known, or suspected autoimmune disease requiring systemic treatment
    5. Subject has known acute or chronic hepatitis
    6. Subject has active pneumonitis or history of ICI-induced pneumonitis that required steroids

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cohorts 1 through 4
Dose escalation and expansion cohorts: KB707 monotherapy in subjects with solid tumor malignancies affecting the lungs.
Biological: KB707
Genetically modified herpes simplex type 1 virus
Experimental: Cohort 5
Dose expansion cohort: KB707 administered in combination with Keytruda in approximately 60 subjects with NSCLC.
Biological: KB707
Genetically modified herpes simplex type 1 virus
Drug: Pembrolizumab (KEYTRUDA®)
PD-1 immune checkpoint inhibitor
Experimental: Cohort 6
Dose expansion cohort: KB707 administered in combination with Keytruda and chemotherapy in approximately 60 subjects with NSCLC.
Biological: KB707
Genetically modified herpes simplex type 1 virus
Drug: Pembrolizumab (KEYTRUDA®)
PD-1 immune checkpoint inhibitor
Drug: Chemotherapy
SOC chemotherapy
Experimental: Experimental: Cohort 7
Dose expansion cohort: KB707 administered in combination with docetaxel in approximately 50 subjects with NSCLC.
Biological: KB707
Genetically modified herpes simplex type 1 virus
Drug: Docetaxel
SOC chemotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)
Time Frame: up to 36 months
Percentage of subjects with treatment-related AEs as assessed by NCI-CTCAE v5
up to 36 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate whether the proposed dose ranges include the maximum tolerated dose of KB707 as determined by incidence of dose limiting toxicities (DLTs)
Time Frame: up to 36 months
Incidence of dose limiting toxicity (DLT) by dose cohorts
up to 36 months
To evaluate the preliminary efficacy of inhaled KB707 as determined by overall response rate (ORR)
Time Frame: up to 36 months
Percentage of ORR for all participants
up to 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Krystal Biotech, Inc.

Investigators

  • Study Director: David Chien, MD, Senior Vice President of Clinical Development

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 17, 2024

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

July 1, 2028

Study Registration Dates

First Submitted

January 18, 2024

First Submitted That Met QC Criteria

January 18, 2024

First Posted (Actual)

January 29, 2024

Study Record Updates

Last Update Posted (Estimated)

October 24, 2025

Last Update Submitted That Met QC Criteria

October 22, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KB707-02

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer Metastatic

Clinical Trials on KB707

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe